Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of...

Prescient’s Leaders Have A Rich History Of Taking Drugs From Bench To Bedside

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of...

Opportunities In Personalised Medicine Industry On Prescient’s Radar

Clinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing personalised medicines to treat a range of challenging cancers. The company...

Journey of Prescient Therapeutics in 2019

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes...

Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio

Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug...

Latest News

Editorial

high dividend-yielding companies

Ten stocks with an Annual Dividend Yield of over 7%

The method by which a company’s earnings are distributed to the shareholders is termed as “dividend”. Dividend yield shows the return on investment in...
Corporate Actions in Two ASX-Listed Infant Formula Stocks

Corporate Actions in Two ASX-Listed Infant Formula Stocks

Consumer staple stocks are non-cyclical in nature, representing products and services that are essential for consumers regardless of their financial situation. Food, beverages, household...